Argentine biosimilar Pembrox forces Merck to cut Keytruda price

Argentine lab ELEA developed Pembrox, a biosimilar of Merck's cancer drug Keytruda, leading Merck to reduce its price. This marks a notable shift in pharmaceutical pricing dynamics, potentially affecting global oncology markets. The extent of the price cut and its broader market impact remain unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works